P fizer today awarded a total of $46 million in financing to four early-stage companies, Cortexyme, 4D Molecular Therapeutics, BioAtla,  NextCure, whose specialties align with the pharma giant’s core areas of R&D interest. Pfizer said the financing represented an expansion of its R&D investment strategy, and would be followed by additional investments in the future.